Back to Search Start Over

Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.

Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.

Authors :
Ye, Peipei
Pei, Renzhi
Jin, Jie
Sun, Jie
Li, Kongfei
Cao, Junjie
Zhou, Dandan
Lu, Ying
Source :
Annals of Hematology. Sep2019, Vol. 98 Issue 9, p2073-2080. 8p.
Publication Year :
2019

Abstract

Patients with primary refractory or early relapsed acute myeloid leukemia (AML) have a dismal prognosis, and the treatment options for these patients are limited. The present study retrospectively examined the efficacy and toxicities of the combination of cladribine 5 mg/m2 per day and intermediate-dose cytarabine 1 g/m2 per day for 5 days and granulocyte colony-stimulating factor (G-CSF) as a salvage treatment in 36 patients with relapsed/refractory AML. Among these, 32 patients had de novo AML, and the remaining 4 patients had secondary AML. The median age for the study cohort was 45.8 years. According to the European LeukemiaNet prognostic index, 5 patients had favorable risk, 18 had intermediate risk, and 11 had poor risk. The complete remission was achieved in 58% of the patients with tolerable toxicities. Fifteen patients underwent stem cell transplantation later. Patients who underwent allogeneic hematopoietic stem cell transplantation had a significantly improved 1-year overall survival compared with those who did not (73% vs. 29%, Pā€‰<ā€‰0.001). The results suggested that, as a salvage regimen, modified cladribine, cytarabine, and G-CSF were effective and well tolerated for patients with relapsed/refractory AML, especially for patients who underwent subsequent stem cell transplantation. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09395555
Volume :
98
Issue :
9
Database :
Academic Search Index
Journal :
Annals of Hematology
Publication Type :
Academic Journal
Accession number :
138140329
Full Text :
https://doi.org/10.1007/s00277-019-03723-w